InflaRx, a biotech company based in Jena, Germany, today published positive data from its exploratory Phase IIa clinical trial with IFX‑1. The trial is for the treatment of hidradenitis suppurativa (HS), a painful, chronic and inflammatory skin disease.
For more information, see:
http://www.bm‑t.com/2017/inflarx-reports-topline-phase-iia-clinical-results-of-ifx-1-for-the-treatment-of-hidradenitis-suppurativa/